A Randomized Phase II Study of S-1 plus Leucovorin versus S-1 alone in Patients with Gemcitabine-Refractory Advanced Pancreatic Cancer.

Trial Profile

A Randomized Phase II Study of S-1 plus Leucovorin versus S-1 alone in Patients with Gemcitabine-Refractory Advanced Pancreatic Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Folinic acid
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical Company
  • Most Recent Events

    • 17 Dec 2015 Results published in the Annals of Oncology
    • 01 Feb 2014 New trial record
    • 27 Sep 2013 Primary endpoint 'Progression-free-survival-duration' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top